Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease

American Journal of Medicine

Volumn 115, Issue 8 SUPPL. 1, 2003, Pages 62-68

  Lyon, Christopher J ^a   Hsueh, Willa A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; FIBROSIS; GLUCOSE TOLERANCE; HUMAN; MORTALITY; PRIORITY JOURNAL; THROMBOSIS;

EID: 0347480398     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.08.014     Document Type: Conference Paper

References (93)

1. Eddy A.A. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 283:2002;F209-F220.
2. Held C., Hjemdahl P., Rehnqvist N., et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol results from the Angina Prognosis Study in Stockholm . Circulation. 95:1997;2380-2386.
3. Thögersen A.M., Jansson J.-H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women evidence for the fibrinolytic system as an independent primary risk factor . Circulation. 98:1998;2241-2247.
4. Scarabin P.-Y., Aillaud M.F., Amouyel P., et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction the PRIME Study . Thromb Haemost. 80:1998;749-756.
5. Bavenholm P., de Faire U., Landou C., et al. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Heart J. 19:1998;402-410.
6. Zunker P., Schick A., Padro T., et al. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke relation to stroke etiology . Neurol Res. 21:1999;727-732.
7. Margaglione M., DiMinno G., Grandone E., et al. Plasma lipoprotein(a) levels in subjects attending a metabolic ward discrimination between individuals with and without a history of ischemic stroke . Arterioscler Thromb Vasc Biol. 16:1996;120-128.
8. Johansson L., Jansson J.-H., Boman K., et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 31:2000;26-32.
9. Eitzman D.T., Westrick R.J., Xu Z., et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 96:2000;4212-4215.
10. Hattori N., Degen J.L., Sisson T.H., et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest. 106:2000;1341-1350.
11. Kaikita K., Fogo A.B., Ma L., et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 104:2001;839-844.
12. Oda T., Jung Y.O., Kim H.S., et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 30:2001;587-596.
13. Lucore C.L., Fujii S., Wun T.-C., et al. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J Biol Chem. 263:1988;15845-15848.
14. Sperti G., van Leeuwen R., Maseri A., Kluft C. Platelet-derived growth factor increases plasminogen activator inhibitor-1 activity and mRNA in rat cultured vascular smooth muscle. Ann N Y Acad Sci. 667:1992;178-180.
15. Konkle B.A., Ginsburg D. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression. J Clin Invest. 82:1988;579-585.
16. Keski-Oja J., Raghow R., Sawdey M., et al. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta divergent responses in lung fibroblasts and carcinoma cells . J Biol Chem. 263:1988;3111-3115.
17. Peraldi M.-N., Rondeau E., Medcalf R.L., et al. Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells. Biochim Biophys Acta. 1134:1992;189-196.
18. Samad F., Yamamoto K., Loskutoff D.J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo induction by tumor necrosis factor-α and lipopolysaccharide . J Clin Invest. 97:1996;37-46.
19. Banfi C., Eriksson P., Giandomenico G., et al. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin insights into the signaling pathway . Diabetes. 50:2001;1522-1530.
20. Reilly C.F., McFall R.C. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem. 266:1991;9419-9427.
21. Feener E.P., Northrup J.M., Aiello L.P., King G.L. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 95:1995;1353-1362.
22. van Leeuwen R.T.J., Kol A., Andreotti F., et al. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 90:1994;362-368.
23. Pepper M.S., Belin D., Montesano R., et al. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol. 111:1990;743-755.
24. Hopkins W.E., Westerhausen D.R. Jr, Sobel B.E., Billadello J.J. Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor. Nucleic Acids Res. 19:1991;163-168.
25. Ottino P., Taheri F., Bazan H.E. Platelet-activating factor induces the gene expression of TIMP-1, -2, and PAI-1 imbalance between the gene expression of MMP-9 and TIMP-1 and -2 . Exp Eye Res. 74:2002;393-402.
26. Michel J.B., Quertermous T. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1. J Immunol. 143:1989;890-895.
27. Sironi L., Mussoni L., Prati L., et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol. 16:1996;89-96.
28. Allison B.A., Nilsson L., Karpe F., et al. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler Thromb Vasc Biol. 19:1999;1354-1360.
29. Chen Y., Billadello J.J., Schneider D.J. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol. 20:2000;2696-2701.
30. Maiello M., Boeri D., Podesta F., et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes. 41:1992;1009-1015.
31. Goldberg H.J., Scholey J., Fantus I.G. Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cells. Diabetes. 49:2000;863-871.
32. Watanabe A., Kurabayashi M., Arai M., et al. Combined effect of retinoic acid and basic FGF on PAI-1 gene expression in vascular smooth muscle cells. Cardiovasc Res. 51:2001;151-159.
33. Takeda K., Ichiki T., Tokunou T., et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol. 21:2001;868-873.
34. Halleux C.M., Declerck P.J., Tran S.L., et al. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue stimulation by glucocorticoids and inhibition by catecholamines . J Clin Endocrinol Metab. 84:1999;4097-4105.
35. Muller J.E. Circadian variation in cardiovascular events. Am J Hypertens. 12:(Pt 2):1999;S35-S42.
36. Braunwald E. Morning resistance to thrombolytic therapy. Circulation. 91:1995;1604-1606.
37. Muller J.E., Stone P.H., Turi Z.G., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 313:1985;1315-1322.
38. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1993;801-809.
39. Schächinger V., Zeiher A.M. Prognostic implications of endothelial dysfunction does it mean anything? Coron Artery Dis. 12:2001;435-443.
40. SuwaidI, JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
41. Cines D.B., Pollack E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:1998;3527-3561.
42. Quyyumi A.A., Dakak N., Andrews N.P., et al. Nitric oxide activity in the human coronary circulation impact of risk factors for coronary atherosclerosis . J Clin Invest. 95:1995;1747-1755.
43. Bouchie J.L., Hansen H., Feener E.P. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells role of cGMP in the regulation of the plasminogen system . Arterioscler Thromb Vasc Biol. 18:1998;1771-1779.
44. Ueno H., Haruno A., Morisaki N., et al. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation. 96:1997;2272-2279.
45. Pannacciulli N., De Mitrio V., Marino R., et al. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res. 10:2002;717-725.
46. Leurs P.B., Stolk R.P., Hamulyak K., et al. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care. 25:2002;1340-1345.
47. Festa A., D'Agostino R. Jr, Mykkänen L., et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance the Insulin Resistance Atherosclerosis Study (IRAS) . Arterioscler Thromb Vasc Biol. 19:1999;562-568.
48. Shimomura I., Funahashi T., Takahashi M., et al. Enhanced expression of PAI-1 in visceral fat possible contributor to vascular disease in obesity . Nat Med. 2:1996;800-803.
49. Primrose J.N., Davies J.A., Prentice C.R.M., et al. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost. 68:1992;396-399.
50. Kockx M., Leenen R., Seidell J., et al. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost. 82:1999;1490-1496.
51. Juhan-Vague I., Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 78:1997;656-660.
52. Alessi M.C., Peiretti F., Morange P., et al. Production of plasminogen activator inhibitor 1 by human adipose tissue possible link between visceral fat accumulation and vascular disease . Diabetes. 46:1997;860-867.
53. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α direct role in obesity-linked insulin resistance . Science. 259:1993;87-91.
54. Cigolini M., Tonoli M., Borgato L., et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue a role for TNF-α? Atherosclerosis. 143:1999;81-90.
55. Sawdey M.S., Loskutoff D.J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β J Clin Invest. 88:1991;1346-1353.
56. Tartare-Deckert S., Chavey C., Monthouel M.-N., et al. The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity. J Biol Chem. 276:2001;22231-22237.
57. Samad F., Loskutoff D.J. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med. 2:1996;568-582.
58. Loskutoff D.J., Samad F. The adipocyte and hemostatic balance in obesity studies of PAI-1 . Arterioscler Thromb Vasc Biol. 18:1998;1-6.
59. Chu N.V., Kong A.P.S., Kimm D.D., et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 25:2002;542-549.
60. Fendri S., Roussel B., Lormeau B., et al. Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects. Metabolism. 47:1998;1372-1375.
61. Carmassi F., Morale M., Ferrini L., et al. Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects. Am J Med. 107:1999;344-350.
62. Aljada A., Ghanim H., Mohanty P., et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab. 87:2002;1419-1422.
63. Cusi K., Maezono K., Osman A., et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 105:2000;311-320.
64. Reusch J.E.B. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol. 90:(suppl):2002;19G-26G.
65. Hsueh W.A., Law R.E. Cardiovascular risk continuum implications of insulin resistance and diabetes . Am J Med. 105:1998;4S-14S.
66. Montagnani M., Golovchenko I., Kim I., et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem. 277:2002;1794-1799.
67. Dlugosz J.A., Munk S., Kapor-Drezgic J., et al. Stretch-induced mesangial cell ERK1/ERK2 activation is enhanced in high glucose by decreased dephosphorylation. Am J Physiol Renal Physiol. 279:2000;F688-F697.
68. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system association of acute-phase reactants and interleukin-6 with metabolic syndrome X . Diabetologia. 40:1997;1286-1292.
69. Yudkin J.S., Stehouwer C.D.A., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects associations with obesity, insulin resistance, and endothelial dysfunction. a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 19:1999;972-978.
70. Hak A.E., Stehouwer C.D.A., Bots M.L., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 19:1999;1986-1991.
71. Festa A., D'Agostino R. Jr, Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes the Insulin Resistance Atherosclerosis Study . Diabetes. 51:2002;1131-1137.
72. Folsom A.R., Qamhieh H.T., Wing R.R., et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 13:1993;162-169.
73. Gris J.-C., Schved J.-F., Feugeas O., et al. Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men. Thromb Haemost. 64:1990;516-520.
74. Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects a study of two ethnic groups . Diabetes Care. 16:1993;621-629.
75. Fonseca V.A., Reynolds T., Hemphill D., et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 12:1998;181-186.
76. Colwell J.A. Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am. 30:2001;1011-1030.
77. Eitzman D.T., McCoy R.D., Zheng X., et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 97:1996;232-237.
78. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 342:2000;1792-1801.
79. Vassalli J.-D., Sappino A.-P., Belin D. The plasminogen activator/ plasmin system. J Clin Invest. 88:1991;1067-1072.
80. Wong A.P., Cortez S.L., Baricos W.H. Role of plasmin and gelatinase in extracellular matrix degradation by cultured rat mesangial cells. Am J Physiol. 263:1992;F1112-F1118.
81. Flaumenhaft R., Rifkin D.B. The extracellular regulation of growth factor action. Mol Biol Cell. 3:1992;1057-1065.
82. van Meijer M., Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis an update . Fibrinolysis. 9:1995;263-276.
83. Freed M., Fuell D., Menci L., et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes [abstract]. Diabetologia. 43:(suppl 1):2000;A267.
84. Ehrmann D.A., Schneider D.J., Sobel B.E., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;2108-2116.
85. Iwamoto Y., Kuzuya T., Matsuda A., et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1991;1083-1086.
86. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-203.
87. Fujiwara T., Yoshioka S., Yoshioka T., et al. Characterization of new oral antidiabetic agent CS-045 studies in KK and ob/ob mice and Zucker fatty rats . Diabetes. 37:1988;1549-1558.
88. Gottschling-Zeller H., Rohrig K., Hauner H. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 43:2000;377-383.
89. Suzuki Y., Urano T., Ihara H., et al. Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in hepG2 cells. Life Sci. 68:2001;1827-1837.
90. Ihara H., Urano T., Takada A., Loskutoff D.J. Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones. FASEB J. 15:2001;1233-1235.
91. Kato K., Satoh H., Endo Y., et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells a possible role for PPARgamma in endothelial function . Biochem Biophys Res Commun. 258:1999;431-435.
92. Nordt T.K., Peter K., Bode C., Sobel B.E. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab. 85:2000;1563-1568.
93. Nilsson L., Takemura T., Eriksson P., Hamsten A. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler Thromb Vasc Biol. 19:1999;1577-1581.